ARMGO Pharma

Heart attack patient with doctor
#ARMGO Pharma #Cardiovascular disease #Heart disease #Phase II trial #Rare disease

Trials of new drug for rare genetic heart disease enter Phase II

ARMGO Pharma has enrolled the first patient in a Phase II proof-of-concept clinical trial using its Rycal ARM210 (also known as S48168), for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT). The trial, performed at the Amsterdam University Medical Center (Amsterdam UMC), Netherlands and the Mayo… Read More

#News